文献速递治疗药物监测与药物基因组学抗菌药物管理

澳大利亚医院抗菌药物新兴治疗药物监测:可及性、性能与实施障碍

Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: Availability, performance and barriers to implementation.
PubMed 文献 · Br J Clin Pharmacol · 2021-07-31

该研究于2019年8-9月对澳大利亚公立和私立医院进行全国横断面调查,评估抗菌药物新兴治疗药物监测(TDM)现状。结果显示仅25%(20/80)医院对8种新兴TDM候选药物中任一品种具备现场检测能力,β-内酰胺类TDM的适应症、药效靶标和采样时间差异大,三大障碍为检测不及时、缺乏机构内专业知识和缺乏指南。

要点

  • 仅25%的澳大利亚医院对新兴抗菌药物TDM具备现场检测能力。
  • β-内酰胺类TDM的适应症、药效靶标和采样时间存在较大差异。
  • 主要障碍为检测不及时、缺乏专业知识和缺乏指南。

核心结论

  • 将新兴TDM证据转化为日常临床实践进展缓慢,需要协调努力解决已识别的障碍并促进标准化实践的实施。

研究设计与样本

  • 2019年8月至9月对澳大利亚公立和私立医院进行的全国横断面调查,共收到82家独特机构的回复,所有29家主要转诊医院均参与。

主要发现

  • 仅25%(20/80)的医院对8种新兴TDM候选药物(β-内酰胺类、抗结核药、氟胞嘧啶、氟喹诺酮类、更昔洛韦、HIV药物、利奈唑胺和替考拉宁)中任一品种具备现场TDM检测能力。
  • TDM采样与结果报告之间存在相当的时间滞后。
  • β-内酰胺类抗生素TDM的适应症、药效靶标和采样时间存在差异。
  • 三大障碍为:缺乏及时的检测/结果、缺乏机构范围内的专业知识和/或培训、缺乏指导TDM开具和结果解读的指南。
  • 大多数受访者支持建立国家TDM指南(89%)和增加剂量预测软件的可及性(96%)。

临床怎么用

  • 临床药师应关注本机构抗菌药物TDM的可及性和时效性,推动建立标准化TDM流程。
  • 针对β-内酰胺类抗生素,需明确本机构的TDM适应症、药效靶标和采样时间。

局限性

  • 调查时间为2019年,可能未反映当前实践。
  • 部分调查问卷未完全填写(5份部分完成)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The purpose of the study was to assess the status of emerging therapeutic drug monitoring (TDM) of anti-infective agents in Australian hospitals. METHODS: A nationwide cross-sectional survey of all Australian hospitals operating in the public and private health sector was conducted between August and September 2019. The survey consisted of questions regarding institutional TDM practice for anti-infective agents and clinical vignettes specific to β-lactam antibiotics. RESULTS: Responses were received from 82 unique institutions, representing all Australian states and territories. All 29 (100%) of principal referral (major) hospitals in Australia participated. Five surveys were partially complete. Only 25% (20/80) of hospitals had TDM testing available on-site for any of the eight emerging TDM candidates considered: β-lactam antibiotics, anti-tuberculous agents, flucytosine, fluoroquinolones, ganciclovir, human immunodeficiency virus (HIV) drugs, linezolid and teicoplanin. A considerable time lag was noted between TDM sampling and reporting of results. With respect to β-lactam antibiotic TDM, variable indications, pharmacodynamic targets and sampling times were identified. The three greatest barriers to local TDM performance were found to be (1) lack of timely assays/results, (2) lack of institutional-wide expertise and/or training and (3) lack of guidelines to inform ordering of TDM and interpretation of results. The majority of respondents favoured establishing national TDM guidelines and increasing access to dose prediction software, at rates of 89% and 96%, respectively. CONCLUSION: Translating emerging TDM evidence into daily clinical practice is slow. Concerted efforts are required to address the barriers identified and facilitate the implementation of standardised practice.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Sandaradura I, Alffenaar JW, Cotta MO, et al. Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: Availability, performance and barriers to implementation. Br J Clin Pharmacol. 2021. PMID: 34289135. doi:10.1111/bcp.14995

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。